Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the gross margin high or low?
The gross margin of 89.36% is 1288% above its 5-year average of -7.52%, near the high end of its 5-year range (-166.11%–100.00%).
Reported quarterly gross margin; no daily interpolation. Q2 FY2026 (2026-06-30): 0.00%.
GROSS MARGIN
89.36%
GROSS MARGIN AVG TTM
0.00%
GROSS MARGIN AVG 3Y
-54.85%
GROSS MARGIN AVG 5Y
-7.52%
GROSS MARGIN AVG 10Y
N/A
GROSS MARGIN AVG 15Y
N/A
GROSS MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
N/A
CURRENT VS 3Y AVG
+262.91%
CURRENT VS 5Y AVG
+1287.72%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
41.20%
median of 862 covered companies
CURRENT VS SECTOR MEDIAN
+116.87%
vs the sector median at left
Whitehawk Therapeutics Inc
Market Cap
$205.80M
Gross Margin
89.36%
TTM Avg
0.00%
3Y Avg
-54.85%
5Y Avg
-7.52%
Market Cap
$210.41M
Gross Margin
83.89%
TTM Avg
91.94%
3Y Avg
70.97%
5Y Avg
47.31%
Market Cap
$210.98M
Gross Margin
-31952.78%
TTM Avg
-15926.39%
3Y Avg
-7913.19%
5Y Avg
-5242.13%
Market Cap
$198.33M
Gross Margin
100.00%
TTM Avg
100.00%
3Y Avg
99.54%
5Y Avg
99.69%
| NAME | MARKET CAP | GROSS MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Whitehawk Therapeutics Inc (WHWK) | $205.80M | 89.36% | 0.00% | -54.85% | -7.52% |
| Pro-Dex, Inc. (PDEX)vs › | $207.27M | 31.38% | 30.34% | 28.84% | 29.64% |
| Electra Therapeutics Inc. (ETRA)vs › | $208.31M | N/A | N/A | N/A | N/A |
| Compugen Ltd. (CGEN)vs › | $209.91M | 86.89% | 79.42% | 84.96% | 87.58% |
| Entrada Therapeutics, Inc. (TRDA)vs › | $210.41M | 83.89% | 91.94% | 70.97% | 47.31% |
| Alector, Inc. (ALEC)vs › | $200.96M | 54.09% | -15.41% | 40.02% | -79.15% |
| Lyell Immunopharma, Inc. (LYEL)vs › | $210.98M | -31952.78% | -15926.39% | -7913.19% | -5242.13% |
| Cartesian Therapeutics, Inc. (RNAC)vs › | $198.33M | 100.00% | 100.00% | 99.54% | 99.69% |
| Exagen Inc. (XGN)vs › | $197.87M | 58.64% | 58.89% | 55.18% | 56.44% |
| Niagen Bioscience Inc (NAGE)vs › | $214.24M | 64.24% | 63.06% | 61.57% | 61.22% |
Gross Margin
89.4%
(Revenue - COGS) / Revenue
Gross Margin = Gross Profit / Revenue
Gross margin is the percentage of revenue remaining after the cost of goods sold, reflecting core product profitability.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | GROSS MARGIN |
|---|---|
| 2026-06-30 | 0.00% |
| 2026-03-31 | 0.00% |
| 2025-12-31 | 0.00% |
| 2025-09-30 | 0.00% |
| 2025-06-30 | 0.00% |
| 2025-03-31 | 89.36% |
| 2024-12-31 | -109.10% |
| 2024-09-30 | -49.76% |
| 2024-06-30 | -124.49% |
| 2024-03-31 | -166.11% |
| 2023-12-31 | -116.49% |
| 2023-09-30 | -111.23% |
| 2023-06-30 | -125.27% |
| 2023-03-31 | 90.98% |
| 2022-12-31 | 95.75% |
| 2022-09-30 | 86.03% |
| 2022-06-30 | 90.08% |
| 2022-03-31 | 92.24% |
| 2021-12-31 | 100.00% |
| 2021-09-30 | 0.00% |
| 2021-06-30 | 0.00% |
| 2021-03-31 | 0.00% |
| 2020-12-31 | 100.00% |
| 2020-09-30 | 0.00% |
| 2020-06-30 | -5099.67% |
| 2020-03-31 | -2289.23% |
